Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising efforts to support a pivotal Phase 2 clinical trial.
Marsden explained that the trial will enrol 450 patients and focus on reducing mortality, which remains high in this population, ranging between 25% to 45%.
